9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

A Study of LY3023414 in Participants With Advanced Cancer

ConditionAdvanced Cancer|Metastatic Cancer|Non-Hodgkin's Lymphoma|Metastatic Breast Cancer|Malignant Mesothelioma|Non-small Cell Lung CancerEstimated Enrollment: 130Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: 13517|I6A-MC-CBBAStudy First Received: July 19, 2012Last Updated: March 22, 2017Estimated Primary Completion Date: March 4, 2018Primary Outcome Measures:Recommended Phase 2 dose|Pharmacokinetics: Maximum concentration (Cmax)|Pharmacokinetics: Time of maximal concentration|Number of participants with tumor response|Potential of LY3023414 to inhibit CYP3A4-mediated metabolismSponsors and Collaborators:Eli Lilly and CompanyResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01655225...

Continue reading

Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy

ConditionOvarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer|Uterine Cancer|Mesotheliomas|Gastrointestinal Cancers|Cervical CancerEstimated Enrollment: 200Age Group: 18 Years to 75 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: HIPECStudy First Received: December 22, 2014Last Updated: January 30, 2017Estimated Primary Completion Date: January 2018Primary Outcome Measures:measure treatment response to HIPEC and tumor debulking|Toxicity MonitoringSponsors and Collaborators:Bay Area Gynecology OncologyResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02349958...

Continue reading

Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed

ConditionPeritoneal Carcinomatosis|Pseudomyxoma Peritonei|Peritoneal MesotheliomaEstimated Enrollment: 125Age Group: Child, Adult, SeniorGender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Case-Only|Time Perspective: ProspectiveStudy ID Numbers: S-54350Study First Received: June 8, 2012Last Updated: July 28, 2016Estimated Primary Completion Date: June 2018Primary Outcome Measures:To improve the prognosis/survival of patients with malignancies localized on the peritoneal surface.Sponsors and Collaborators:Universitaire Ziekenhuizen LeuvenResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01617382...

Continue reading

uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung

ConditionNon-small Cell Lung Cancer|Malignant Pleural Mesothelioma|Large Cell Neuroendocrine Carcinoma of the LungEstimated Enrollment: 120Age Group: 18 Years to 85 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open LabelStudy ID Numbers: AK-2015-LC-1Study First Received: April 19, 2016Last Updated: November 18, 2016Estimated Primary Completion Date: April 2023Primary Outcome Measures:Study Ia: Overall survival (OS)|Study Ib: Overall survival (OS)|Study II and III: Uptake of 68Ga-NOTA-AE105 in primary tumor lesion (dichotomized +/-)|Study Ia: Progression free survival (PFS)|Study Ib: Disease free survival (DFS)Sponsors and Collaborators:Rigshospitalet, DenmarkResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02755675...

Continue reading

Clinical and Histopathologic Characteristics of BAP1 Mutations

ConditionMalignant Pleural Mesothelioma (MPM)|Choroidal Nevus|Primary Uveal Melanoma (UM)|Metastatic Uveal Melanoma (UM)|Renal Cell Carcinoma|CholangiocarcinomaEstimated Enrollment: 460Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Cohort|Time Perspective: ProspectiveStudy ID Numbers: 12-235Study First Received: January 18, 2013Last Updated: January 27, 2017Estimated Primary Completion Date: January 2018Primary Outcome Measures:determine the prevalence of germline BAP1 mutations|prevalence of somatic BAP1 mutations in disease mesothelioma and metastatic uveal melanoma.Sponsors and Collaborators:Memorial Sloan Kettering Cancer Center|United States Department of DefenseResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01773655...

Continue reading

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

ConditionPleural Mesothelioma Malignant Advanced|Peritoneal Mesothelioma Malignant Advanced|Non-squamous Non-small Cell Lung Carcinoma Stage IIIB/IV (NSCLC)|Metastatic Uveal Melanoma|Hepatocellular Carcinoma (HCC)|Glioma|Sarcomatoid CancersEstimated Enrollment: 88Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: POLARIS2013-006Study First Received: December 16, 2013Last Updated: April 3, 2017Estimated Primary Completion Date: August 2018Primary Outcome Measures:Define initial estimates of efficacy, measured by RECIST 1.1 criteria for non-squamous NSCLC, advanced peritoneal mesothelioma, metastatic uveal melanoma, HCC, glioma and sarcomatoid cancers for ADI-PEG 20 in combination with pemetrexed and cisplatin.|Define initial estimates of efficacy, measured by...

Continue reading

Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM

ConditionNon Small Cell Lung Cancer (NSCLC)|Malignant Pleural Mesothelioma (MPM)Estimated Enrollment: 32Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 2014-53Study First Received: September 11, 2015Last Updated: September 18, 2015Estimated Primary Completion Date: August 2018Primary Outcome Measures:Phase IA : Treatment-related hematological toxicities (neutropenia) of grade 3-4 as assessed by CTCAE v4.0|Phase IB : Objective response rate according to RECIST1.1 for NSCLC and RECIST1.1 modified for MPMSponsors and Collaborators:Assistance Publique Hopitaux De MarseilleResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02555007...

Continue reading

MPM PDT Phase II Trial

ConditionEpitheliod Malignant Pleural MesotheliomaEstimated Enrollment: 102Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Primary Purpose: TreatmentStudy ID Numbers: UPCC 14513Study First Received: May 28, 2014Last Updated: December 6, 2016Estimated Primary Completion Date: May 2018Primary Outcome Measures:Number of adverse eventsSponsors and Collaborators:Abramson Cancer Center of the University of PennsylvaniaResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02153229...

Continue reading

SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access

ConditionAny Stage of Lung Cancer (Any Histotype)|Any Stage of Malignant Pleural Mesothelioma|Any Stage of Any Thymic MalignancyEstimated Enrollment: 3500Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Cohort|Time Perspective: ProspectiveStudy ID Numbers: EORTC-1335-LCG-PBGStudy First Received: August 7, 2014Last Updated: January 17, 2017Estimated Primary Completion Date: January 2019Primary Outcome Measures:Number of patients with thoracic malignancy (lung cancer, MPM and thymic malignancies) screened and efficiently allocated to biomarker-driven clinical trials.|Number of patients for whom the description of the biomarkers and correlation to clinical/pathological characteristics can be performed.|Number of exploratory/future research projects developpedSponsors and Collaborators:European Organisation...

Continue reading

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

ConditionMedical OncologyEstimated Enrollment: 30Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: 17631Study First Received: November 30, 2015Last Updated: April 12, 2017Estimated Primary Completion Date: March 26, 2018Primary Outcome Measures:Maximum tolerated dose (MTD)|Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability|Plasma concentrations of anetumab ravtansine (BAY 94-9343), pemetrexed and cisplatin|Tumor response evaluation following mRECIST criteria to determine the number of patients with CR, PR, SD or PD|Number of patients with a positive titer of anti-drug antibodiesSponsors...

Continue reading